Analyst keeps Buy on Sana Biotechnology, adjusts outlook as …

Nov 11, 2024 · In other recent news, Sana Biotechnology has maintained its Buy rating and $8.00 price target from H.C. Wainwright, following the announcement of its third-quarter 2024 …

$8.00
OFF

Analyst Keeps Buy On Sana Biotechnology, Adjusts Outlook As …

2 weeks from now

Nov 11, 2024 · In other recent news, Sana Biotechnology has maintained its Buy rating and $8.00 price target from H.C. Wainwright, following the announcement of its third-quarter 2024 …

investing.com

$8.00
OFF

Analyst Keeps Buy On Sana Biotechnology, Adjusts Outlook As …

2 weeks from now

Nov 11, 2024 · On Monday (NASDAQ: MNDY), H.C. Wainwright maintained a Buy rating and an $8.00 price target on shares of Sana Biotechnology (NASDAQ:SANA), following the …

investing.com

$8
OFF

Sana Biotech Stock Target Cut, Buy Rating Held On Pipeline ...

2 weeks from now

Nov 5, 2024 · On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sana Biotechnology (NASDAQ:SANA), reducing the price target to $8 from the previous $11 while maintaining a …

investing.com

$15.00
OFF

Citi Keeps Their Buy Rating On Sana Biotechnology (SANA)

2 weeks from now

Jan 8, 2025 · Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a price target of $15.00. The company’s shares …

businessinsider.com

$15.00
OFF

Optimistic Buy Rating For Sana Biotechnology Amid Strategic ...

2 weeks from now

Nov 8, 2024 · Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a price target of $15.00.. Samantha Semenkow …

businessinsider.com

$7
OFF

Sana Biotechnology Price Target Lowered To $7 From $8 At BofA

2 weeks from now

Jan 7, 2025 · BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $7 from $8 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an …

businessinsider.com

7%
OFF

Sana Biotechnology (NASDAQ:SANA) Trading Up 5.7% - Still A Buy?

2 weeks from now

1 day ago · Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share …

marketbeat.com

200%
OFF

Sana Biotech Stock Jumps On Cell Therapy Data (SANA:NASDAQ)

2 weeks from now

Jan 8, 2025 · Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell …

seekingalpha.com

FAQs about Analyst keeps Buy on Sana Biotechnology, adjusts outlook as … Coupon?

Should you buy Sana biotechnology (Sana – research report)?

Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $1.65. According to TipRanks, Semenkow is an analyst with an average return of -19.5% and a 26.32% success rate. ...

What is the price target for Sana biotechnology (Sana)?

The highest price target for SANA is $16.00, while the lowest price target for SANA is $11.00. The average price target represents a forecasted upside of 231.40% from the current price of $4.30. Enter your email address to receive the latest news and analysts' ratings for Sana Biotechnology and its competitors. ...

Should you buy Sana biotechnology (semenkow) stock?

Semenkow covers the Healthcare sector, focusing on stocks such as Argenx Se, Larimar Therapeutics, and Sana Biotechnology. Sana Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $9.75, representing a 490.91% upside. ...

Why has Samantha semenkow rated Sana biotechnology a buy?

Samantha Semenkow has given her Buy rating due to a combination of factors that contribute to an optimistic outlook for Sana Biotechnology. Despite delays in the data release for their Type 1 Diabetes (T1D) program, the underlying fundamentals remain strong. ...

Why did Sana biotechnology (Sana) rise 200%?

Sana Biotechnology (NASDAQ: SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according to Morgan Stanley, has de-risked the company's hypoimmune (HIP) therapeutic platform. ...

Why did Sana biotechnology stock soared after Phase 1 data?

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has de-risked its HIP platform. Read more here. ...